| Title |
A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells
|
|---|---|
| Published in |
AMB Express, June 2017
|
| DOI | 10.1186/s13568-017-0410-5 |
| Pubmed ID | |
| Authors |
Solmaz Agha Amiri, Soraya Shahhosseini, Najmeh Zarei, Dorsa Khorasanizadeh, Elahe Aminollahi, Faegheh Rezaie, Mehryar Zargari, Mohammad Azizi, Vahid Khalaj |
| Abstract |
CD22 marker is a highly internalizing antigen which is located on the surface of B-cells and is being used as a promising target for treatment of B cell malignancies. Monoclonal antibodies targeting CD22 have been introduced and some are currently under investigation in clinical trials. Building on the success of antibody drug conjugates, we developed a fusion protein consisting of a novel anti-CD22 scFv and apoptin and tested binding and therapeutic effects in lymphoma cells. The recombinant protein was expressed in E. coli and successfully purified and refolded. In vitro binding analysis by immunofluorescence and flow cytometry demonstrated that the recombinant protein specifically binds to CD22 positive Raji cells but not to CD22 negative Jurkat cells. The cytotoxic properties of scFv-apoptin were assessed by an MTT assay and Annexin V/PI flow cytometry analysis and showed that the recombinant protein induced apoptosis preferentially in Raji cells with no detectable effects in Jurkat cells. Our findings indicated that the recombinant anti-CD22 scFv-apoptin fusion protein could successfully cross the cell membrane and induce apoptosis with high specificity, make it as a promising molecule for immunotherapy of B-cell malignancies. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 16% |
| Student > Ph. D. Student | 4 | 16% |
| Student > Bachelor | 3 | 12% |
| Student > Master | 2 | 8% |
| Lecturer | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 8 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 8 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Environmental Science | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 10 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2017.
All research outputs
#15,462,982
of 22,977,819 outputs
Outputs from AMB Express
#446
of 1,239 outputs
Outputs of similar age
#199,459
of 317,446 outputs
Outputs of similar age from AMB Express
#39
of 72 outputs
Altmetric has tracked 22,977,819 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,239 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,446 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.